Clearbridge Health Limited

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023, 2022, 2020, 2019

In its 2023 reporting, Clearbridge Health Limited disclosed greenhouse gas emissions of 201.5 tCO2e. By scope: Scope 2: 201.5 tCO2e. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
201.5 tCO2e
2023
♻️
Waste
8.9K kg (hazardous and non-hazardous)
2023
⚙️
Energy Use
329.1K kWh
2023

📊 Emissions by Scope (2023)

ScopeWhat it coversReported value
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.201.5 tCO2e

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
2023201.5 tCO2e
2022195.8 tCO2e

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Maintain zero incidents of non-compliance with relevant laws and regulations
  • Maintain zero confirmed incidents of corruption
  • Maintain zero known cases of identified leaks, thefts or losses of customer data

📅 Medium-term

  • Continue to review and identify opportunities to improve energy efficiency
  • Consider premises with renewable energy when relocating its premises

🌱 ESG Focus Areas

Upholding Good Governance and EthicsProviding Quality HealthcareDeveloping Our Human CapitalPreparing for Climate Change ResiliencyProtecting our Environment

⚠️ Challenges & Risks +

  • High inflation, coupled with slow growth and its impact on consumer spending, which may in turn impact the consumption of the products and services the Group provides.
  • Inflation may raise the cost of goods for the Group and negatively impact the Group’s profit margins.
  • Decreased revenue from the distribution of Labnovation’s COVID-19 ART Test Kits in Hong Kong and Philippines and a decrease in revenue from the medical clinics/centres in Singapore and Philippines for the provision of general medical, dental and clinical services and distribution of medical and pharmaceutical products.
  • Impairment losses arising from a reduction in the estimated recoverable value of the Group’s goodwill from previously acquired assets due to the decrease in the financial performance of the medical clinics/centres segment.
  • Allowance for expected credit losses mainly arising from a reduction in the entire recoverable value of the receivables owing by SAM Laboratory Pte. Ltd. and Clearbridge Medical Asia Pte. Ltd.

📋 Report Information

Reporting Period: 2023
Frameworks: GRI 2021 Standards, TCFD Recommendations, UN SDGs